A Phase 3 interventional study of Trastuzumab Deruxtecan and Bevacizumab in Ovarian Cancer, sponsored by Daiichi Sankyo. Recruiting at 232 sites in 26 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Daiichi Sankyo · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Ovarian Neoplasms by Daiichi Sankyo — 5 open to participants now, 6 under way, 3 of them phase 3. Ovarian Neoplasms · Daiichi Sankyo.
Among the 12 studies in Ovarian Neoplasms by Daiichi Sankyo, this one is one of 2 that started in 2025, is one of 2 in phase 3, and was the 10th registered.
3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →5 of the 12 studies in Ovarian Neoplasms by Daiichi Sankyo are open now, in 12 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in United States, Argentina, Australia and 15 more countries
Ages 18+
Daiichi Sankyo · Sites in United States, Australia, Brazil and 16 more countries
Ages 18+
Daiichi Sankyo · Sites in United States, Australia, Belgium and 13 more countries
Ages 18+
Daiichi Sankyo
Ages 18+ · Women only
By country, each count listing its studies:
Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 3
First in 1999; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 582 is above the median of 54 across 2,553 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 582 across the 9 interventional studies, 415 across the 2 observational. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Daiichi Sankyo is the lead sponsor of 322 studies on the registry; 37 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 38 (75%) have results posted.
2 of the studies in Ovarian Neoplasms by Daiichi Sankyo that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04707248Daiichi SankyoA Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors | 2026-12-30 |
| NCT06172478Daiichi SankyoA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | 2027-09-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Ovarian Neoplasms by Daiichi Sankyo, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry [IHC] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.
A non-randomized safety run-in phase will be conducted prior to randomization phase to assess the safety of T-DXd in combination with bevacizumab.
The criteria were revised on the registry on Oct 28, 2026. See what changed
Key Inclusion Criteria:
Sign and date the tissue prescreening form (ICF), prior to central testing. Sign and date the Main ICF prior to the start of any trial- specific qualification procedures. Consent to optional PGx prior to any PGx procedures.
*For participants in the safety run-in phase, a safety run-in ICF needs to be signed and dated prior to the start of any trial-specific qualification procedures.
Key Exclusion Criteria:
Previous cerebral-vascular accident, or subarachnoid hemorrhage within 6 months prior to randomization.
*Note: For participants enrolled from the Republic of Korea, country-specific requirements are applicable.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive T-DXd in combination with bevacizumab.
Drug: Trastuzumab Deruxtecan · Drug: Bevacizumab
Participants will receive bevacizumab monotherapy.
Drug: Bevacizumab
T-DXd will be administered at a dose of 5.4 mg/kg intravenously (IV) every 3 weeks (Q3W).
Also known as: T-DXd, ENHERTU®
Bevacizumab will be administered at a dose of 15 mg/kg IV Q3W.
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) in the HER2 IHC 3+/2+ Population
Time from randomization to time of objective radiographic disease progression as assessed by BICR based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) or death due to any cause.
Time frame: From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months
Overall Survival (OS) in the HER2 IHC 3+/2+ Population
Time interval from the date of randomization to the date of death due to any cause.
Time frame: From date of randomization to death due to any cause, up to approximately 72 months
PFS by BICR in the HER2 IHC 3+/2+/1+ Population
Time from randomization to time of objective radiographic disease progression as assessed by BICR based on RECIST v1.1 or death due to any cause.
Time frame: From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months
OS in the HER2 IHC 3+/2+/1+ Population
Time interval from the date of randomization to the date of death due to any cause.
Time frame: From date of randomization to death due to any cause, up to approximately 72 months
PFS by the Investigator in HER2 IHC 3+/2+ Population
Time from randomization to time of objective radiographic disease progression as assessed by the investigator based on RECIST v1.1 or death due to any cause.
Time frame: From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months
PFS by the Investigator in HER2 IHC 3+/2+/1+ Population
Time from randomization to time of objective radiographic disease progression as assessed by the investigator based on RECIST v1.1 or death due to any cause.
Time frame: From date of randomization to radiographic disease progression or death due to any cause, up to approximately 35 months
Progression Free Survival 2 (PFS2) by the Investigator in HER2 IHC 3+/2+ Population
Time from date of randomization to the first documented progression on subsequent systemic therapy by investigator assessment, or death due to any cause, whichever occurs first.
Time frame: From date of randomization to first documented progression or death due to any cause, up to approximately 72 months
PFS2 by the Investigator in HER2 IHC 3+/2+/1+ Population
Time from date of randomization to the first documented progression on subsequent systemic therapy by investigator assessment, or death due to any cause, whichever occurs first.
Time frame: From date of randomization to first documented progression or death due to any cause, up to approximately 72 months
Confirmed Objective Response (OR) by BICR in HER2 IHC 3+/2+ Population
OR is defined as participants with best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) assessed by BICR according to RECIST v1.1. CR: Disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: At least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Up to approximately 35 months
Confirmed OR by the Investigator in HER2 IHC 3+/2+ Population
OR is defined as participants with BOR of confirmed CR or confirmed PR assessed by the investigator, according to RECIST v1.1. CR: Disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Up to approximately 35 months
Confirmed OR by BICR in HER2 3+/2+/1+ Population
OR is defined as participants with BOR of confirmed CR or confirmed PR as assessed by BICR according to RECIST v1.1. CR: Disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Up to approximately 35 months
Confirmed OR by the Investigator in HER2 IHC 3+/2+/1+ Population
OR is defined as participants with BOR of confirmed CR or confirmed PR assessed by the investigator, according to RECIST v1.1. CR: Disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Up to approximately 35 months
Duration of Response (DoR) by BICR in HER2 IHC 3+/2+ Population
Time from the date of first documentation of objective tumor response (CR or PR), that is subsequently confirmed by BICR, to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. CR: Disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Up to approximately 35 months
DoR by the Investigator in HER2 IHC 3+/2+ Population
Time from the date of first documentation of objective tumor response (CR or PR), that is subsequently confirmed by investigator, to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. CR: Disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Up to approximately 35 months
DoR by BICR in HER2 IHC 3+/2+/1+ Population
Time from the date of first documentation of objective tumor response (CR or PR), that is subsequently confirmed by BICR, to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. CR: Disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Up to approximately 35 months
DoR by the Investigator in HER2 IHC 3+/2+/1+ Population
Time from the date of first documentation of objective tumor response (CR or PR), that is subsequently confirmed by investigator, to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. CR: Disappearance of all target lesions and non-target lesions and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Up to approximately 35 months
Time to First Subsequent Treatment (TFST) in HER2 IHC 3+/2+ Population
Time from randomization until the start date of the first subsequent anticancer therapy after discontinuation of randomized treatment, or death due to any cause.
Time frame: Up to approximately 72 months
TFST in HER2 IHC 3+/2+/1+ Population
Time from randomization until the start date of the first subsequent anticancer therapy after discontinuation of randomized treatment, or death due to any cause.
Time frame: Up to approximately 72 months
Time to Second Subsequent Treatment (TSST) in HER2 IHC 3+/2+ Population
Time from randomization until the start date of the second subsequent anticancer therapy after discontinuation of first subsequent treatment, or death due to any cause.
Time frame: Up to approximately 72 months
TSST in HER2 3+/2+/1+ Population
Time from randomization until the start date of the second subsequent anticancer therapy after discontinuation of first subsequent treatment, or death due to any cause.
Time frame: Up to approximately 72 months
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs are defined as those AEs with start or worsening date during the on-treatment period (from the first dose date of trial intervention to 47 days after the last dose date of trial intervention).
Time frame: Up to approximately 82 months
Change from Baseline in Physical Function from European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire 30 (QLQ-C30)
The EORTC QLQ-C30 assesses 5 functional scales, 3 symptom scales, a global health/QoL scale, and 6 single items. The physical functional scale is scored on a 4-point scale ranging from 1 ("not at all") to 4 ("very much"). Scores are linearly transformed on a scale of 0 to 100. A higher scale score represents better functioning.
Time frame: Baseline up to approximately 72 months
Change from Baseline in Pain from EORTC QLQ-C30
The EORTC QLQ-C30 assesses 5 functional scales, 3 symptom scales, a global health/QoL scale, and 6 single items. The pain symptom scale is scored on a 4-point scale ranging from 1 ("not at all") to 4 ("very much"). Scores are linearly transformed on a scale of 0 to 100. A higher scale score represents worse symptom.
Time frame: Baseline up to approximately 72 months
Change from Baseline in Global Health Status/Overall Quality of Life (GHS/Overall QoL) Scales from EORTC QLQ-C30
The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status.
Time frame: Baseline up to approximately 72 months
Change from Baseline in Abdominal/Gastrointestinal (GI) Symptoms from EORTC Quality of Life Questionnaire Ovarian Cancer Module 28 (QLQ-OV28)
EORTC QLQ-OV28 is an ovarian cancer-specific module to supplement the EORTC QLQ-C30. Participant responses to the 6 abdominal/GI symptoms scale questions are scored on a 4-point scale (1=not at all, 4=very much). The combined score is computed by averaging the raw scores of the 6 items and then applying a linear transformation to standardize the average score, so that the combined score ranges from 0 to 100. The change from baseline in abdominal and gastrointestinal symptoms (EORTC QLQ-OV28 Items 31-36) score will be presented. A lower score indicates a better outcome.
Time frame: Baseline up to approximately 72 months
Percentage of Participants With Confirmed Deterioration for Physical function, Pain, GHS/Overall QoL scales from EORTC QLQ-C30
The EORTC QLQ-C30 assesses 5 functional scales, 3 symptom scales, a global health/QoL scale, and 6 single items. The functional, symptom, and single items are scored on a 4-point scale ranging from 1 ("not at all") to 4 ("very much"). The final 2 global health/QoL items are scored on a 7-point scale ranging from 1 ("very poor") to 7 ("excellent"). All of the scales and single-item measure scores are linearly transformed on a scale of 0 to 100. A higher scale score represents a higher response level and worse symptoms for the symptom scales.
Time frame: Up to approximately 72 months
Percentage of Participants With Confirmed Deterioration Abdominal/Gastrointestinal Symptoms from EORTC QLQ-OV28
EORTC QLQ-OV28 is an ovarian cancer-specific module to supplement the EORTC QLQ-C30. Participant responses to the 6 abdominal/GI symptoms scale questions are scored on a 4-point scale (1=not at all, 4=very much). The combined score is computed by averaging the raw scores of the 6 items and then applying a linear transformation to standardize the average score, so that the combined score ranges from 0 to 100. The change from baseline in abdominal and gastrointestinal symptoms (EORTC QLQ-OV28 Items 31-36) score will be presented. A lower score indicates a better outcome.
Time frame: Up to approximately 72 months
Time to Confirmed Deterioration for Physical Function, Pain, GHS/Overall QoL Scales from EORTC QLQ-C30
The EORTC QLQ-C30 assesses 5 functional scales, 3 symptom scales, a global health/QoL scale, and 6 single items. The functional, symptom, and single items are scored on a 4-point scale ranging from 1 ("not at all") to 4 ("very much"). The final 2 global health/QoL items are scored on a 7-point scale ranging from 1 ("very poor") to 7 ("excellent"). All of the scales and single-item measure scores are linearly transformed on a scale of 0 to 100. A higher scale score represents a higher response level and worse symptoms for the symptom scales.
Time frame: Up to approximately 72 months
Time to Confirmed Deterioration for Abdominal/Gastrointestinal Symptoms from EORTC QLQ-OV28
EORTC QLQ-OV28 is an ovarian cancer-specific module to supplement the EORTC QLQ-C30. Participant responses to the 6 abdominal/GI symptoms scale questions are scored on a 4-point scale (1=not at all, 4=very much). The combined score is computed by averaging the raw scores of the 6 items and then applying a linear transformation to standardize the average score, so that the combined score ranges from 0 to 100. The change from baseline in abdominal and gastrointestinal symptoms (EORTC QLQ-OV28 Items 31-36) score will be presented. A lower score indicates a better outcome.
Time frame: Up to approximately 72 months
Showing the first 100 of 232 sites across 26 countries. Choose a country and city above to see the rest.
Plan to share: Yes — De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Nov 2028, 43 months after the start.
Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 43 months is close to that.
Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab deruxtecan